About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in San Antonio | 1,334 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisSan Antonio

Rheumatoid Arthritis Clinical Trials in San Antonio

Find 1,334 clinical trials for rheumatoid arthritis near San Antonio, Texas. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in San Antonio

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 821-840 of 1,334 trials

COMPLETEDPHASE4< 1 mile

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

NCT00632385

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.127 participantsStarted Jan 2003

Irvine, California, United States • Newport Beach, California, United States • San Francisco, California, United States +13 more locations

COMPLETEDPHASE3< 1 mile

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

NCT00264875

To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy

Peripheral NeuropathyHIV Infections

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.220 participantsStarted Feb 2006

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +34 more locations

Rheumatoid Arthritis Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPHASE1< 1 mile

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

NCT03417778

The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.

Rheumatoid Arthritis

Gilead Sciences20 participantsStarted Apr 2018

Miami, Florida, United States • San Antonio, Texas, United States • Munich, Germany +1 more locations

COMPLETEDPHASE3< 1 mile

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474

The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The medical condition treated in the core and extension trials was neo-vascular age-related macular degeneration (nAMD).

Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals151 participantsStarted Jan 2018

Peoria, Arizona, United States • Phoenix, Arizona, United States • Arcadia, California, United States +62 more locations

COMPLETEDPHASE374 miles

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

NCT03354598

This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract infection (uUTI) in adult women

Uncomplicated Urinary Tract Infections

Iterum Therapeutics, International Limited1,671 participantsStarted Aug 2018

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tolleson, Arizona, United States +57 more locations

COMPLETEDPHASE289 miles

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456

This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least moderate nausea during their last cycle of low emetogenic chemotherapy.

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Eisai Inc.36 participantsStarted Oct 2009

Sunrise, Florida, United States • Galesburg, Illinois, United States • Skokie, Illinois, United States +6 more locations

COMPLETEDPHASE1/PHASE2190 miles

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

NCT01445080

This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more

National Cancer Institute (NCI)70 participantsStarted May 2006

Birmingham, Alabama, United States • Orange, California, United States • Palo Alto, California, United States +22 more locations

UNKNOWNPHASE3190 miles

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

NCT02847429

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.

GIST With D842V Mutated PDGFRA Gene

Arog Pharmaceuticals, Inc.120 participantsStarted Aug 2016

Santa Monica, California, United States • Miami, Florida, United States • Durham, North Carolina, United States +20 more locations

COMPLETEDPHASE3190 miles

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03682302

Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries. Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.

Postoperative Pain Management

Pacira Pharmaceuticals, Inc98 participantsStarted Apr 2019

Loma Linda, California, United States • Sacramento, California, United States • Stanford, California, United States +14 more locations

COMPLETEDPHASE3190 miles

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

NCT01820572

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.

Kidney Transplantation

Bristol-Myers Squibb446 participantsStarted Mar 2013

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Loma Linda, California, United States +114 more locations

UNKNOWN190 miles

Gliogene: Brain Tumor Linkage Study

NCT00418899

The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a family's genes and increase the risk of developing gliomas. Objectives: We propose an international multi-center, multidisciplinary study consortium, GLIOGENE, to identify susceptibility genes in high-risk familial brain tumor pedigrees using the most sophisticated genetic analysis methods available. To address our hypothesis, we propose the following specific aims: Aim 1: Establish a cohort of 400 high-risk pedigrees for genetic linkage analysis. To date, we have identified and collected biologic samples from 20 high-risk families that have met our criteria of 2 or more relatives diagnosed with a brain tumor. From the 15 centers in the United States and Europe, we will screen and obtain epidemiologic data from approximately 17,080 gliomas cases to identify a target of 400 families for genetic analysis. We will establish a cohort of the first and second-degree relatives from these glioma cases to obtain new knowledge about how cancer aggregates in glioma families. We will also acquire biospecimens (blood and tumor tissue), and risk factor data from relevant family members. Aim 2: Identify candidate regions linked to familial brain tumors. To strengthen evidence of linkage to regions found in our preliminary analysis and to identify additional regions linked to brain tumors, we will genotype informative glioma pedigrees identified in aim 1 using Affymetrix 10K GeneChip with markers spaced throughout the genome, and conduct a genome-wide multipoint linkage scan with these markers. Aim 3: Fine map the regions established in Aim 2 by genotyping selected SNPs from genome databases. We will attempt to further refine the regions identified in Aim 2 to less than 1cM by using approximately 1,500 - 2,000 carefully selected SNPs. The prioritization of regions will be based on a combination of the strength of evidence for linkage from families of various ethnic backgrounds and the presence of obvious candidate genes.

Brain TumorGlioma

M.D. Anderson Cancer Center17,080 participantsStarted Feb 2004

San Francisco, California, United States • Tampa, Florida, United States • Chicago, Illinois, United States +12 more locations

COMPLETEDPHASE2190 miles

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

NCT01851083

Pediatric severe traumatic brain injury (TBI) is the leading cause of death and disability in children ages 1-14 years old. There are no effective therapies to treat secondary brain injury and the post-injury response of CNS apoptosis and neuroinflammation. This study is a follow-up trial from a previously performed Phase I trial that demonstrated the safety and potential CNS structural preservation effect of intravenous autologous bone marrow mononuclear cells (BMMNC) after severe TBI in children. (Cox, 2011) The study is designed as a prospective, randomized, placebo controlled, blinded Phase 2 safety/biological activity study. The investigators hope to determine the effect of intravenous infusion of autologous BMMNCs on brain structure and neurocognitive/functional outcomes after severe TBI in children.

Traumatic Brain Injury

The University of Texas Health Science Center, Houston47 participantsStarted Aug 2013

Phoenix, Arizona, United States • Houston, Texas, United States

COMPLETEDNA253 miles

TRANSFIX Zenith® Transection Clinical Study

NCT01688050

The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.

Thoracic AortaThoracic InjuriesBlunt Injuries

Cook Research Incorporated50 participantsStarted Jan 2013

Little Rock, Arkansas, United States • Los Angeles, California, United States • Los Angeles, California, United States +18 more locations

COMPLETEDNA277 miles

Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

NCT03277378

Prospective, multi-center, randomized, single blind study

Chronic, Intractable Pain of the Trunk and/or Lower Limbs

Abbott Medical Devices270 participantsStarted Sep 2017

Santa Rosa, California, United States • Clearwater, Florida, United States • Merritt Island, Florida, United States +22 more locations

COMPLETEDPHASE2575 miles

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876

The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune response. In the current study, COPD patients with a history of acute exacerbations will receive 2 doses of the investigational vaccine or placebo intramuscularly according to a 0, 2 month vaccination schedule, in addition to standard care. The effect of vaccination against two pathogens known to cause exacerbations (Non-typeable Haemophilus influenza \[NTHi\] and Moraxella catarrhalis \[Mcat\]) will be evaluated at pre-defined timepoints (scheduled study visits). In addition to the scheduled study visits, additional study visit(s) and/ or phone contact(s) will take place for each acute exacerbation of COPD occurring from first vaccination up to study conclusion.

Respiratory Disorders

GlaxoSmithKline606 participantsStarted Nov 2017

Mesa, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +64 more locations

COMPLETEDNA632 miles

TX2® Low Profile TAA Endovascular Graft

NCT01151020

The Zenith® TX2® Low Profile TAA Endovascular Graft study is a clinical trial approved by US FDA to evaluate the safety and effectiveness of the Zenith® TX2® Low Profile TAA Endovascular Graft indicated for the treatment of patients with aneurysms/ulcers of the descending thoracic aorta having vessel structure suitable for repair.

Aortic AneurysmPenetrating UlcerVascular Disease

Cook Research Incorporated110 participantsStarted Mar 2010

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Tampa, Florida, United States +30 more locations

COMPLETEDPHASE2744 miles

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

NCT01064791

This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo renal transplantation.

Renal Transplantation

Novartis Pharmaceuticals298 participantsStarted Dec 2009

Birmingham, Alabama, United States • Aurora, Colorado, United States • Ann Arbor, Michigan, United States +41 more locations

COMPLETEDPHASE2798 miles

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

NCT00411528

The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.

Metastatic Hormone Refractory Prostate Cancer

Novartis Pharmaceuticals185 participantsStarted Sep 2006

La Jolla, California, United States • Aurora, Colorado, United States • Norwalk, Connecticut, United States +29 more locations

TERMINATEDPHASE3847 miles

Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2)

NCT01908751

The purpose of this study is to determine the impact of surgical fixation (cancellous screws versus sliding hip screws) and biologic intervention (Vitamin D versus placebo) on patient important outcomes.

Femoral Neck Fractures

McMaster University91 participantsStarted Sep 2014

Phoenix, Arizona, United States • San Francisco, California, United States • Gainesville, Florida, United States +17 more locations

TERMINATEDPHASE1/PHASE21087 miles

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

NCT01562899

This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study will be guided by a Bayesian Logistic Regression Model (BLRM). At least 18 patients are expected to be enrolled in the dose escalation part. Following MTD/ RP2D declaration, patients will be enrolled in three phase II arms to assess efficacy of the combination as well as to better understand the safety, tolerability, PK, antibody concentrations and PD of the combination at MTD/RP2D. Phase II arm 1 will consist of approximately 25 patients with KRAS-mutant colorectal adenocarcinoma. Phase II arm 2 will consist of approximately 20 patients with metastatic pancreatic adenocarcinoma. Phase II arm 3 will consist of approximately 28 patients with mutant BRAFV600 melanoma. Patients will be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurs first. All patients will be followed up - at minimum patients must complete the safety follow-up assessments 30 days after the last dose of the study treatment.

Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma

Pfizer77 participantsStarted Aug 2012

Boston, Massachusetts, United States • Salt Lake City, Utah, United States • Parkville, Victoria, Australia +6 more locations

PreviousPage 42 of 67Next

Other Conditions in San Antonio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia